Understanding the theoretical underpinnings behind VC-induced AAT resistance, and delving into the intricate landscape of the tumor immune microenvironment within VC may yield fresh insights and innovative approaches toward precision-based therapies for liver cancer. The gene discussed is SERPINA1; the disease is neoplasm.